GEA Group Aktiengesellschaft Q3 Earnings Call Highlights

Key Points

• GEA delivered strong Q3 growth: Organic order intake rose 19.5%, sales increased 7% to about EUR 1.5 billion, and EBITDA before restructuring expenses grew 12.6% to EUR 261 million, with a record 17.9% margin.
• Large projects and pharmaceutical demand supported orders: Orders above EUR 15 million totaled EUR 295 million, versus EUR 64 million a year earlier. The backlog was 20% higher year over year, supporting management’s expectation of significant growth next year.
• GEA reaffirmed its 2026 outlook for 6%–8% organic sales growth and a 17.0%–17.4% EBITDA margin, and said sales growth was likely to land near the top of the range. It also received EUR 103 million in orders for continuous tablet manufacturing lines and is expanding production capacity.

GEA Group Aktiengesellschaft ETR: G1A reported a 19.5% increase in organic order intake in the third quarter of 2026, as large projects and demand for pharmaceutical equipment helped lift profitability to a record level.

Sales rose 7% to approximately EUR 1.5 billion, while EBITDA before restructuring expenses increased 12.6% to EUR 261 million. The corresponding margin expanded 0.9 percentage points from a year earlier to 17.9%, Chief Financial Officer Alexander Kocherscheidt said.

Chief Executive Officer Stefan Klebert said the company’s order backlog was 20% higher than at the end of the third quarter of 2025, supporting his expectation of significant growth next year. GEA confirmed its full-year guidance, which it had raised in July.

Large orders drive growth

Orders worth more than EUR 15 million totaled EUR 295 million in the quarter, compared with EUR 64 million a year earlier. Klebert said smaller base orders, those below EUR 1 million, also grew strongly.

All divisions contributed to organic order growth, Kocherscheidt said, with particularly strong demand from dairy processing, beverage and pharmaceutical customers. Organic sales rose 6.2%, including an 8.6% increase in service sales and a 4.6% gain in new machine sales. Services accounted for 40.9% of group sales, up 0.8 percentage points.

Nutrition Plant Engineering posted organic order growth of almost 38%, supported by EUR 192 million in large orders from dairy processing and beverage customers. Its EBITDA margin before restructuring expenses rose to 11.8% from 11.4% a year earlier.

Pure Flow Processing reported organic order growth of 8.3% and a 26.9% EBITDA margin. Pharma & Food Applications’ orders rose 20.2%, and its margin increased 2.8 percentage points to 16.1%. Farm Technologies’ organic orders grew 4.1%, while its margin fell to 16.4% from 18%, primarily because of product mix and a strong prior-year comparison, Kocherscheidt said.

Tablet technology draws orders

GEA secured EUR 103 million in orders for continuous tablet manufacturing lines during the quarter. Klebert said the amount represented multiple orders rather than a single customer contract.

Unlike conventional batch processing, continuous tableting integrates production into a powder-to-tablet process with real-time monitoring and quality controls. Klebert said the technology can reduce production time by more than 90%, lower the cost per tablet by up to 40% and use up to 30% less factory space.

Klebert said margins on the technology were significantly better, and that service requirements should be of a similar magnitude to existing equipment. He added that GEA was doubling its tablet-pressing capacity and building an additional factory in Belgium.

The CEO said customers do not always disclose what they intend to produce on the machines. Asked about potential demand associated with GLP-1 weight-loss drugs, he said such products could add to demand but emphasized the broader market for tablets.

Klebert also said GEA’s earlier Mission 30 target for the technology—15% to 20% annual growth and revenue of EUR 50 million to EUR 150 million in 2030—might prove too conservative.

Cash position and outlook

GEA generated EUR 135 million in free cash flow during the quarter and ended September with net cash of EUR 115 million, despite spending on its share buyback. The company had executed EUR 58 million of its program of up to EUR 500 million by September 30, Klebert said.

For 2026, management reaffirmed its forecast for organic sales growth of 6% to 8%, an EBITDA margin before restructuring expenses of 17.0% to 17.4%, and return on capital employed of 36% to 40%. Klebert said sales growth was most likely to finish toward the upper end of the guidance range.

He cautioned that fourth-quarter order intake would not match the prior-year quarter, which included an unusually large Baladna project. However, he said the company still had a strong pipeline and expected a good fourth quarter, while noting that the timing of large orders can be difficult to predict.

About GEA Group Aktiengesellschaft (ETR:G1A)

GEA Group Aktiengesellschaft engages in the development and production of systems and components to the food, beverage, and pharmaceutical industries. It operates through Separation & Flow Technologies, Liquid & Power Technologies, Food & Health Technologies, Farm Technologies, and Heating & Refrigeration Technologies segments. The Separation & Flow Technologies segment manufacture process-related components and machinery including notably separators, decanters, homogenizers, valves, and pumps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.